title: Beneficial effects of montelukast against cisplatin-induced acute renal damage in rats.
abstract: OBJECTIVE
  In this study, the therapeutic and protective effects of montelukast against cisplatin (CP)-induced acute renal damage were investigated.
  
  
  METHODS
  Thirty-five female rats were divided into five groups as follows: (1) control, (2) montelukast (10 mg/kg daily for 10 days per-oral (p.o.), (3) CP (single dose 7 mg/kg intraperitoneally (i.p.)), (4) CP + montelukast (10 mg/kg daily for 10 days p.o., after 3 days of the injection of CP), (5) montelukast (10 mg/kg daily for 10 days p.o.) + CP (single dose 7 mg/kg i.p., after the last dose of montelukast). At the end of the experiment, malondialdehyde (MDA), a lipid peroxidation product, myeloperoxidase (MPO), and reduced glutathione (GSH) levels were determined in the renal tissue. Also, blood urea nitrogen (BUN) and creatinine (Cr) levels were assayed from the trunk blood samples.
  
  
  RESULTS
  CP treatment caused a significant elevation of MDA, MPO, BUN, and Cr levels when compared with the control group. Also, GSH levels were found to be reduced due to the CP treatment. Montelukast administration after CP injection ameliorated all of these parameters. Our histopathological findings (marked swelling of epithelial cells, tubular dilatation, tubular desquamation, and loss of brush border in the kidney) were consistent with the biochemical results.
  
  
  CONCLUSIONS
  Montelukast treatment after CP injection exerted therapeutic effects against CP-induced acute kidney damage.
authors.affiliation: Department of Urology, Medical Faculty, Inonu University, Malatya, Turkey. ali.beytur@inonu.edu.tr
authors.forename: Ali
authors.initials: A
authors.lastname: Beytur
authors.forename: Evren
authors.initials: E
authors.lastname: Köse
authors.forename: Mehmet Ediz
authors.initials: ME
authors.lastname: Sarihan
authors.forename: Hilal Irmak
authors.initials: HI
authors.lastname: Sapmaz
authors.forename: Zumrut
authors.initials: Z
authors.lastname: Dogan
authors.forename: Asli
authors.initials: A
authors.lastname: Cetin
authors.forename: Nigar
authors.initials: N
authors.lastname: Vardi
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Turkoz
authors.forename: Nihat
authors.initials: N
authors.lastname: Ekinci
mesh_terms: D000085:Acetates / Q000008:administration & dosage*; D058186:Acute Kidney Injury / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D001806:Blood Urea Nitrogen; D002945:Cisplatin / Q000633:toxicity; D003404:Creatinine / Q000378:metabolism; D003521:Cyclopropanes; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D005978:Glutathione / Q000378:metabolism; D007274:Injections, Intraperitoneal; D007668:Kidney / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D008315:Malondialdehyde / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D009195:Peroxidase / Q000378:metabolism; D011804:Quinolines / Q000008:administration & dosage*; D051381:Rats; D017208:Rats, Wistar; D013053:Spectrophotometry; D013440:Sulfides; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D008315:Malondialdehyde; D003404:Creatinine; D009195:Peroxidase; D005978:Glutathione; C093875:montelukast; D002945:Cisplatin